scispace - formally typeset
C

Carmelo Lafuente-Lafuente

Researcher at University of Paris

Publications -  55
Citations -  1391

Carmelo Lafuente-Lafuente is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Heart failure. The author has an hindex of 14, co-authored 46 publications receiving 1128 citations. Previous affiliations of Carmelo Lafuente-Lafuente include Pierre-and-Marie-Curie University & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

TL;DR: Several class IA, IC and III drugs, as well as class II drugs (beta-blockers), are moderately effective in maintaining sinus rhythm after conversion of atrial fibrillation, but they increase adverse events and are associated with increased all-cause mortality.
Journal ArticleDOI

Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.

TL;DR: Class IA, IC, and III drugs are effective in maintaining sinus rhythm but increase adverse effects, and class IA drugs may increase mortality.
Journal ArticleDOI

Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation

TL;DR: Amiodarone has been demonstrated to be the most effective drug in maintaining sinus rhythm and increasing mortality and dronedarone possibly decreasing the incidence of serious adverse events and proarrhythmia.
Journal ArticleDOI

Active chest compression-decompression for cardiopulmonary resuscitation.

TL;DR: Active chest compression-decompression in patients with cardiac arrest is not associated with clear benefit and assessment of neurological outcome was limited and there were few patients with neurological damage.
Journal ArticleDOI

Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity.

TL;DR: No evidence of excessive or unexpected accumulation of amiodarone in fat tissue on long-term administration is found, and late amioarone adverse effects, particularly hypothyroidism, are associated with longer exposure times, but do not seem to be explained by higher concentrations in plasma or infat tissue.